New vaccine aims to train immune system against lymphoma

NCT ID NCT04669171

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Enterome Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new vaccine (EO2463) designed to help the immune system fight indolent non-Hodgkin's lymphoma, a slow-growing blood cancer. About 80 adults with follicular or marginal zone lymphoma will receive the vaccine alone or combined with standard drugs lenalidomide and rituximab. The goal is to find the safest and most effective dose.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA MARGINAL ZONE LYMPHOMA

Contacts and locations

Locations

CHU d'Amiens-Picardie - Hopital SUD
RECRUITING

Amiens, France
Clinica Universidad de Navarra
RECRUITING

Madrid, Spain
Clinica Universidad de Navarra
RECRUITING

Pamplona, Spain
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Hospital Clinico Universitario de Salamanca
RECRUITING

Salamanca, Spain
IRCCS Policlinico San Matteo Foundation - University of Pavia
RECRUITING

Naples, Italy
IRCCS Policlinico San Matteo Foundation - University of Pavia
RECRUITING

Pavia, Italy
Mayo Clinic
RECRUITING

Rochester, Minnesota, 55905, United States
University Hospital Vall d'Hebron, Institute of Oncology
RECRUITING

Barcelona, Spain
University of Bologna
WITHDRAWN

Bologna, Italy
University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)
RECRUITING

Rochester, New York, 14642, United States
University of Washington-Seattle Cancer Care Alliance
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.